PE20230245A1 - Inhibidores de prmt5 - Google Patents
Inhibidores de prmt5Info
- Publication number
- PE20230245A1 PE20230245A1 PE2021002071A PE2021002071A PE20230245A1 PE 20230245 A1 PE20230245 A1 PE 20230245A1 PE 2021002071 A PE2021002071 A PE 2021002071A PE 2021002071 A PE2021002071 A PE 2021002071A PE 20230245 A1 PE20230245 A1 PE 20230245A1
- Authority
- PE
- Peru
- Prior art keywords
- substituted
- compound
- prmt5
- bond
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201921022971 | 2019-06-10 | ||
| IN201921022972 | 2019-06-10 | ||
| PCT/IB2020/055401 WO2020250123A1 (en) | 2019-06-10 | 2020-06-09 | Prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230245A1 true PE20230245A1 (es) | 2023-02-07 |
Family
ID=71670318
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002071A PE20230245A1 (es) | 2019-06-10 | 2020-06-09 | Inhibidores de prmt5 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US20220315589A1 (lt) |
| EP (1) | EP3980417B1 (lt) |
| JP (1) | JP2022536337A (lt) |
| KR (1) | KR20220019781A (lt) |
| CN (1) | CN114026094B (lt) |
| AU (1) | AU2020293021A1 (lt) |
| BR (1) | BR112021024999A2 (lt) |
| CA (1) | CA3141748A1 (lt) |
| CL (1) | CL2021003292A1 (lt) |
| CO (1) | CO2022000061A2 (lt) |
| CR (1) | CR20220010A (lt) |
| DK (1) | DK3980417T3 (lt) |
| EC (1) | ECSP22001370A (lt) |
| ES (1) | ES2967457T3 (lt) |
| FI (1) | FI3980417T3 (lt) |
| HR (1) | HRP20231673T1 (lt) |
| HU (1) | HUE064493T2 (lt) |
| IL (1) | IL288401A (lt) |
| LT (1) | LT3980417T (lt) |
| MX (1) | MX2021015262A (lt) |
| PE (1) | PE20230245A1 (lt) |
| PL (1) | PL3980417T3 (lt) |
| PT (1) | PT3980417T (lt) |
| RS (1) | RS64972B1 (lt) |
| SI (1) | SI3980417T1 (lt) |
| WO (1) | WO2020250123A1 (lt) |
| ZA (1) | ZA202109573B (lt) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022271540A1 (en) * | 2021-06-21 | 2022-12-29 | Mayo Foundation For Medical Education And Research | Inhibitors of dot1l |
| WO2023278564A1 (en) * | 2021-07-02 | 2023-01-05 | Mirati Therapeutics, Inc. | Aminopyridine-based mta-cooperative prmt5 inhibitors |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| TWI412322B (zh) | 2005-12-30 | 2013-10-21 | Du Pont | 控制無脊椎害蟲之異唑啉 |
| AR064415A1 (es) | 2006-12-21 | 2009-04-01 | Cancer Rec Tech Ltd | Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb. |
| CA2707105C (en) | 2007-12-11 | 2013-02-12 | F. Hoffmann-La Roche Ag | Inhibitors of stearoyl-coa desaturase |
| US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
| KR101715414B1 (ko) | 2008-11-14 | 2017-03-10 | 메리얼 인코포레이티드 | 거울상 이성질체가 풍부한 아릴로아졸-2-일 시아노에틸아미노 구충 화합물 |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
| RU2560163C2 (ru) | 2010-06-30 | 2015-08-20 | Фуджифилм Корпорэйшн | Новое производное никотинамида или его соль |
| WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| EP2619198A1 (en) | 2010-09-22 | 2013-07-31 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| AU2013250726B2 (en) * | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| KR102173874B1 (ko) | 2012-12-21 | 2020-11-05 | 에피자임, 인코포레이티드 | 테트라하이드로- 및 디하이드로-이소퀴놀린 prmt5 억제제 및 이의 용도 |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| EP2935247B1 (en) | 2012-12-21 | 2019-08-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP2016505001A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | Ｐｒｍｔ５阻害剤およびその使用 |
| EP2935240A1 (en) * | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| US9856218B2 (en) | 2013-03-15 | 2018-01-02 | Ohio State Innovation Foundation | Inhibitors of PRMT5 and methods of their use |
| KR20160076519A (ko) | 2013-10-10 | 2016-06-30 | 아락세스 파마 엘엘씨 | Kras g12c 억제제 |
| PE20170146A1 (es) | 2014-06-25 | 2017-03-08 | Glaxosmithkline Ip Dev Ltd | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016022605A1 (en) | 2014-08-04 | 2016-02-11 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016034671A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
| US10494376B2 (en) | 2014-09-03 | 2019-12-03 | Ctxt Pty. Ltd. | Tetrahydroisoquinoline derived PRMT5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| US20180010132A1 (en) | 2014-09-11 | 2018-01-11 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| JP6584521B2 (ja) | 2015-02-24 | 2019-10-02 | ファイザー・インク | 抗がん剤として有用な置換ヌクレオシド誘導体 |
| WO2016145150A2 (en) | 2015-03-11 | 2016-09-15 | The Broad Institute Inc. | Selective treatment of prmt5 dependent cancer |
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI791251B (zh) * | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| TW201722957A (zh) | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產（第二）有限公司 | 化學化合物 |
| CA2969295A1 (en) | 2016-06-06 | 2017-12-06 | Pfizer Inc. | Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor |
| WO2018085818A1 (en) | 2016-11-07 | 2018-05-11 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| WO2018152501A1 (en) | 2017-02-20 | 2018-08-23 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| EA201990851A1 (ru) | 2017-02-24 | 2019-09-30 | Янссен Фармацевтика Нв | Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5 |
| WO2018160824A1 (en) | 2017-03-01 | 2018-09-07 | Prelude Therapeutics, Incorporated | Selective inhibitors of protein arginine methyltransferase 5 (prmt5) |
| US11098026B2 (en) | 2017-03-13 | 2021-08-24 | Impetis Biosciences Limited | Fused bicyclic compounds, compositions and applications thereof |
| HRP20221207T1 (hr) * | 2017-12-13 | 2022-12-09 | Lupin Limited | Supstituirani biciklički heterociklički spojevi kao inhibitori prmt5 |
-
2020
- 2020-06-09 BR BR112021024999A patent/BR112021024999A2/pt unknown
- 2020-06-09 CA CA3141748A patent/CA3141748A1/en active Pending
- 2020-06-09 EP EP20742922.6A patent/EP3980417B1/en active Active
- 2020-06-09 WO PCT/IB2020/055401 patent/WO2020250123A1/en active Application Filing
- 2020-06-09 PT PT207429226T patent/PT3980417T/pt unknown
- 2020-06-09 AU AU2020293021A patent/AU2020293021A1/en active Pending
- 2020-06-09 LT LTEPPCT/IB2020/055401T patent/LT3980417T/lt unknown
- 2020-06-09 CR CR20220010A patent/CR20220010A/es unknown
- 2020-06-09 HU HUE20742922A patent/HUE064493T2/hu unknown
- 2020-06-09 PE PE2021002071A patent/PE20230245A1/es unknown
- 2020-06-09 MX MX2021015262A patent/MX2021015262A/es unknown
- 2020-06-09 SI SI202030344T patent/SI3980417T1/sl unknown
- 2020-06-09 CN CN202080042550.3A patent/CN114026094B/zh active Active
- 2020-06-09 JP JP2021573236A patent/JP2022536337A/ja active Pending
- 2020-06-09 RS RS20231219A patent/RS64972B1/sr unknown
- 2020-06-09 HR HRP20231673TT patent/HRP20231673T1/hr unknown
- 2020-06-09 DK DK20742922.6T patent/DK3980417T3/da active
- 2020-06-09 US US17/618,042 patent/US20220315589A1/en active Pending
- 2020-06-09 FI FIEP20742922.6T patent/FI3980417T3/fi active
- 2020-06-09 PL PL20742922.6T patent/PL3980417T3/pl unknown
- 2020-06-09 ES ES20742922T patent/ES2967457T3/es active Active
- 2020-06-09 KR KR1020227000720A patent/KR20220019781A/ko unknown
-
2021
- 2021-11-25 ZA ZA2021/09573A patent/ZA202109573B/en unknown
- 2021-11-25 IL IL288401A patent/IL288401A/en unknown
- 2021-12-10 CL CL2021003292A patent/CL2021003292A1/es unknown
-
2022
- 2022-01-06 CO CONC2022/0000061A patent/CO2022000061A2/es unknown
- 2022-01-07 EC ECSENADI20221370A patent/ECSP22001370A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN114026094A (zh) | 2022-02-08 |
| PT3980417T (pt) | 2023-12-28 |
| ECSP22001370A (es) | 2022-02-25 |
| CO2022000061A2 (es) | 2022-04-08 |
| HUE064493T2 (hu) | 2024-03-28 |
| SI3980417T1 (sl) | 2024-02-29 |
| CL2021003292A1 (es) | 2022-08-19 |
| EP3980417B1 (en) | 2023-09-27 |
| KR20220019781A (ko) | 2022-02-17 |
| PL3980417T3 (pl) | 2024-03-18 |
| LT3980417T (lt) | 2023-12-27 |
| US20220315589A1 (en) | 2022-10-06 |
| HRP20231673T1 (hr) | 2024-03-15 |
| CR20220010A (es) | 2022-05-13 |
| FI3980417T3 (fi) | 2023-12-28 |
| AU2020293021A1 (en) | 2021-12-23 |
| DK3980417T3 (en) | 2023-12-18 |
| RS64972B1 (sr) | 2024-01-31 |
| BR112021024999A2 (pt) | 2022-01-25 |
| JP2022536337A (ja) | 2022-08-15 |
| WO2020250123A1 (en) | 2020-12-17 |
| EP3980417A1 (en) | 2022-04-13 |
| IL288401A (en) | 2022-01-01 |
| CA3141748A1 (en) | 2020-12-17 |
| ES2967457T3 (es) | 2024-04-30 |
| MX2021015262A (es) | 2022-04-06 |
| ZA202109573B (en) | 2022-11-30 |
| CN114026094B (zh) | 2024-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211444A1 (es) | Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5 | |
| DOP2022000278A (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| PE20230245A1 (es) | Inhibidores de prmt5 | |
| PE20241068A1 (es) | Moduladores de profarmacos de la via de estres integrada | |
| ECSP21027049A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| CL2020002198A1 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b. | |
| CO2019008531A2 (es) | Análogos de atazanavir (atv) para tratar infecciones por vih. | |
| PE20221457A1 (es) | Degradadores de moleculas pequenas de helios y procedimientos de uso | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| MA42678B1 (fr) | Nouveaux analogues nucléosidiques substitués à cycle aromatique bicyclique 6-6 pour une utilisation en tant qu'inhibiteurs de prmt5 | |
| CO6531444A2 (es) | Métodos sintéticos para compuestos espiro-oxoindol | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| PE20190806A1 (es) | Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos | |
| AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
| GEP20247638B (en) | Pharmaceutical combination of prmt5 inhibitors | |
| CO2022003457A2 (es) | Triazolopirimidinas como inhibidores de a2a/a2b | |
| AR050914A1 (es) | Agonista receptor de vasopresina peptidico | |
| CO2019010578A2 (es) | Derivados de fenilo como moduladores del receptor de pge2 | |
| MA39335A1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| CL2022000374A1 (es) | Métodos para preparar análogos de incretina | |
| EA202092253A1 (ru) | Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5 | |
| EA202191968A1 (ru) | Новые замещенные производные сульфонилмочевины | |
| PE20211006A1 (es) | Derivados de azitromicina y roxitromicina como farmacos senoliticos | |
| BR112021024469A2 (pt) | Métodos para tratamento de câncer com o uso de inibidores de prmt5 |